Use of hydroxy‐methyl‐glutaryl coenzyme A reductase inhibitors is associated with risk of lymphoid malignancies
Open Access
- 25 January 2006
- journal article
- Published by Wiley in Cancer Science
- Vol. 97 (2) , 133-138
- https://doi.org/10.1111/j.1349-7006.2006.00153.x
Abstract
It has been speculated that the use of hydroxy‐methyl‐glutaryl coenzyme A reductase inhibitors (statins) is associated with the risk of malignant diseases. Considering their immunosuppressive activities, malignant diseases that are associated with an immunosuppressive status seem feasible to examine the association. We therefore examined the association between statin use and development of lymphoid malignancies in a case‐control study. Cases were 221 consecutive incident cases with histopathologically proven lymphoid malignancies (lymphoma and myeloma), hospitalized in the Department of Hematology of Toranomon Hospital (Tokyo, Japan) between 1995 and 2001. Two independent control groups, comprising 442 and 437 inpatients without malignancies from the Departments of Orthopedics and Otorhinolaryngology of the same hospital, were selected to test for consistency of association. Controls were matched individually with cases for age, sex and year of admission. Subject information, including statin use, was abstracted from medical records at the time of hospitalization. Strength of association was evaluated as an adjusted odds ratios (aOR) using a conditional logistic regression model. A higher frequency of statin use was found among patients with lymphoid malignancies in comparison with both orthopedic (aOR 2.11, 95% CI 1.20–3.69, P = 0.009) and otorhinolaryngology patients (aOR 2.59, 95% CI 1.45–4.65, P = 0.001), the significance being maintained when the two control groups were combined (aOR 2.24, 95% CI 1.37–3.66, P = 0.001). In conclusion, we observed an elevated risk of lymphoid malignancy with statin use among Japanese patients. Further evaluations in different populations are required to draw conclusions as to the carcinogenicity of lymphoid malignancies with statin use. (Cancer Sci 2006; 97: 133 –138)This publication has 37 references indexed in Scilit:
- Statins and Prostate Cancer Risk: A Case-Control StudyAmerican Journal of Epidemiology, 2005
- Cancer risk among statin users: A population‐based cohort studyInternational Journal of Cancer, 2004
- HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosisLeukemia, 2002
- Statins Have Biphasic Effects on AngiogenesisCirculation, 2002
- Alcohol, Smoking, and Dietary Status and Susceptibility to Malignant Lymphoma in Japan: Results of a Hospital-based Case-control Study at Aichi Cancer CenterJapanese Journal of Cancer Research, 2001
- Epstein–Barr Virus InfectionNew England Journal of Medicine, 2000
- Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol LevelsNew England Journal of Medicine, 1998
- Non-Hodgkin's lymphoma after kidney or heart transplantation: frequency of occurrence during the first posttransplant yearTransplant International, 1994
- Dietary factors and non‐Hodgkin's lymphoma: A case‐control study in the northeastern part of ItalyNutrition and Cancer, 1989
- Proposals for the classification of the myelodysplastic syndromesBritish Journal of Haematology, 1982